Asthma
Conditions
Keywords
Adult, asthma, Fluticasone Propionate, Adolescents, Salmeterol, Vilanterol, ELLIPTA, ACCUHALER/DISKUS, Non-inferior, Fluticasone Furoate
Brief summary
This study is a randomized, double-blind, double-dummy, parallel group, multicenter, non-inferiority study. The study will enroll adult and adolescent asthmatic subjects who are currently receiving mid dose inhaled corticosteroids (ICS) plus long-acting beta2-agonist (LABA) (equivalent to fluticasone propionate \[FP\]/salmeterol 250/50 microgram \[mcg\]twice daily \[BD\]), either via a fixed dose combination product or through separate inhalers. The study consists of a LABA washout period of 5 days and a run-in period of 4 weeks, followed by a treatment period of 24 weeks, and a follow up contact period of one week. The total duration of the study is 30 weeks. Approximately 1461 subjects will be randomized to one of the following three treatments (487 per treatment): fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg once daily (OD) in the evening (PM) via ELLIPTA™ inhaler plus placebo BD via ACCUHALER™/DISKUS™; FP/salmeterol 250/50 mcg BD via ACCUHALER/DISKUS inhaler plus placebo OD (PM) via ELLIPTA inhaler; FP 250 mcg BD via ACCUHALER/DISKUS inhaler plus placebo OD (PM) via ELLIPTA inhaler. In addition, all subjects will be supplied with albuterol/salbutamol inhalation aerosol to use as needed to treat acute asthma symptoms. This study will determine if FF/VI 100/25 mcg OD via ELLIPTA inhaler is non-inferior to FP/salmeterol 250/50 mcg BD via ACCUHALER/DISKUS inhaler in adult and adolescent asthmatic subjects already adequately controlled on a twice-daily ICS/LABA. SERETIDE, ELLIPTA, ACCUHALER, RELVAR, and DISKUS are trademarks of the GlaxoSmithKline Group of Companies.
Interventions
DRUGFluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler
FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
DRUGPlacebo inhalation powders via ELLIPTA inhaler
Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
DRUGFluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler
FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
DRUGPlacebo inhalation powder via ACCUHALER/DISKUS inhaler
Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
DRUGFluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must give their signed and dated written informed consent to participate prior to commencing any study related activities. * Subjects must be outpatients \>=12 years of age at Visit 1 who have had a diagnosis of asthma, as defined by the National Institutes of Health, for at least 12 weeks prior to Visit 1 (Note: Countries with local restrictions prohibiting enrollment of adolescents will enroll subjects \>=18 years of age only). * Subjects may be male or an eligible female. An eligible female is defined as having non-childbearing potential or having childbearing potential and a negative urine pregnancy test at Screening and agrees to use an acceptable method of birth control consistently and correctly. * Subjects must have a FEV1 of \>=80% of the predicted normal value. * Subjects are eligible if they have received mid dose ICS plus LABA (equivalent to FP/salmeterol 250/50 twice daily or an equivalent combination via separate inhalers) for at least the 12 weeks immediately preceding Visit 1. * All subjects must be able to replace their current SABA treatment with albuterol/salbutamol aerosol inhaler at Visit 1 for use, as needed, for the duration of the study. Subjects must be able to withhold albuterol/salbutamol for at least 6 hours prior to study visits. * If in the opinion of the investigator the subject's asthma is well controlled.
Exclusion criteria
* History of Life-Threatening Asthma, defined for this protocol as an asthma episode that required intubation and/or associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 5 years. * Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or in the opinion of the Investigator, expected to affect the subject's asthma status or the subject's ability to participate in the study. * Any asthma exacerbation requiring oral corticosteroids within 12 weeks of Visit 1 or resulting in an overnight hospitalization requiring additional treatment for asthma within 6 months prior to Visit 1. * A subject must not have current evidence of Atlectasis, Bronchopulmonary dysplasia, Chronic bronchitis, Chronic obstructive pulmonary disease, Pneumonia, Pneumothorax, Interstitial lung disease, or any evidence of concurrent respiratory disease other than asthma * A subject must not have any clinically significant, uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study. * A subject must not have used any investigational drug within 30 days prior to Visit 1 or within five half-lives (t½) of the prior investigational study, whichever is longer of the two. * Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of RELVAR™ ELLIPTA inhaler, SERETIDE™ ACCUHALER/DISKUS inhaler or FP 250. * History of severe milk protein allergy. * Administration of prescription or non-prescription medication that would significantly affect the course of asthma, or interact with study drug. * A subject must not be using or require the use of immunosuppressive medications during the study. * A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, disease, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol, including visit schedule and completion of the daily diaries. * Current tobacco smoker or has a smoking history of 10 pack-years (20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products or inhaled marijuana within the past 3 months (e.g., cigarettes, cigars, electronic cigarettes, or pipe tobacco). * A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population | Baseline and Week 24 | FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the mixed model repeated measures (MMRM) model and least square mean and standard error were calculated. The analysis was performed on ITT Population which comprised of all participants randomized to treatment and who received at least one dose of study medication. |
| Change From Baseline in PM FEV1 Using Per Protocol (PP) Population | Baseline and Week 24 | FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the MMRM models and least square mean and standard error were calculated. The analysis was performed on PP Population which comprised of all participants in the ITT Population who did not had any full protocol deviations. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF) | Baseline and Weeks 1-24 | PEF was measured using an electric flow meter each morning. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated. |
| Change From Baseline in the Percentage of Rescue-free 24-hour Periods | Baseline and Weeks 1-24 | The number of inhalations of rescue medication used during the day and night were recorded by participants using an electronic diary (e-diary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated. |
| Change From Baseline in PM PEF | Baseline and Weeks 1-24 | PEF was measured using an electric flow meter each evening. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated. |
| Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20 | Week 24 | The ACT was a five-item questionnaire developed as a measure of participant's asthma control. The percentage of participants controlled, defined as having ACT score greater than or equal to 20 at the end of Week 24 were analyzed using logistic regression model with covariates of Baseline ACT score, region, sex, age and treatment group. |
| Change From Baseline in the Percentage of Symptom-free 24-hour Periods | Baseline and Weeks 1-24 | Change from Baseline in the percentage of symptom-free 24 hour period was evaluated. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value.Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated. |
Countries
Argentina, Brazil, Chile, Czechia, Germany, Mexico, Netherlands, Romania, Russia, South Korea, Spain, United States
Participant flow
Recruitment details
Eligible participants at screening and run-in visits entered a 24 Week treatment period and were randomized to receive either Fluticasone furoate/Vilanterol (FF/VI) 100/25 micrograms (mcg) or Fluticasone propionate/salmeterol (FP/S) 250/50mcg or only FP 250mcg followed by a follow-up phase. The total duration for study participation was 30 weeks.
Pre-assignment details
A total of 3162 adult and adolescent participants with asthma were screened, out of which 516 were screen-failures, 1124 were run-in failures, 1522 participants were randomized, and 1504 subjects received at least one dose of study medication to be included in the Intent-to-Treat (ITT) Population.
Participants by arm
| Arm | Count |
|---|---|
| FF/VI 100/25 mcg Once Daily Participants received FF/VI 100/25 mcg via ELLIPTA® inhaler once daily (at evening) along with placebo via ACCUHALER/DISKUS® twice daily for 24 weeks. Albuterol/Salbutamol inhalation aerosol was also provided to treat acute asthma symptoms. | 504 |
| FP/S 250/50 mcg Twice Daily Participants received FP/S 250/50 mcg via ACCUHALER/DISKUS inhaler twice daily along with placebo via ELLIPTA inhaler once daily (at evening) for 24 weeks. Albuterol/Salbutamol inhalation aerosol was also provided to treat acute asthma symptoms. | 501 |
| FP 250 mcg Twice Daily Participants received FP 250 mcg via ACCUHALER/DISKUS inhaler twice daily along with placebo via ELLIPTA inhaler once daily (at evening) for 24 weeks. Albuterol/Salbutamol inhalation aerosol was also provided to treat acute asthma symptoms. | 499 |
| Total | 1,504 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 8 | 3 | 2 |
| Overall Study | Lack of Efficacy | 1 | 1 | 1 |
| Overall Study | Lost to Follow-up | 0 | 2 | 2 |
| Overall Study | Physician Decision | 4 | 2 | 3 |
| Overall Study | Protocol Violation | 3 | 5 | 3 |
| Overall Study | Withdrawal by Subject | 15 | 12 | 11 |
Baseline characteristics
| Characteristic | Total | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|---|
| Age, Continuous | 43.5 Participants STANDARD_DEVIATION 16.04 | 44.4 Participants STANDARD_DEVIATION 16.3 | 43.0 Participants STANDARD_DEVIATION 15.2 | 43.0 Participants STANDARD_DEVIATION 16.58 |
| Race/Ethnicity, Customized African American/ African and White Heritage | 5 Participants | 0 Participants | 5 Participants | 0 Participants |
| Race/Ethnicity, Customized American Indian/Alaskan Native and White Heritage | 192 Participants | 66 Participants | 62 Participants | 64 Participants |
| Race/Ethnicity, Customized American Indian or Alaska native | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian - East Asian and White Heritage | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian - East Asian Heritage | 23 Participants | 8 Participants | 11 Participants | 4 Participants |
| Race/Ethnicity, Customized Asian- Japanese Heritage | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian- South East Asian Heritage | 2 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black/African American Heritage | 43 Participants | 12 Participants | 14 Participants | 17 Participants |
| Race/Ethnicity, Customized White- Arabic/ North African Heritage | 3 Participants | 0 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized White- Mixed White Race | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White- White/Caucasian/European Heritage | 1232 Participants | 415 Participants | 407 Participants | 410 Participants |
| Sex: Female, Male Female | 964 Participants | 314 Participants | 336 Participants | 314 Participants |
| Sex: Female, Male Male | 540 Participants | 190 Participants | 165 Participants | 185 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 504 | 0 / 501 | 0 / 499 |
| other Total, other adverse events | 126 / 504 | 123 / 501 | 124 / 499 |
| serious Total, serious adverse events | 6 / 504 | 4 / 501 | 5 / 499 |
Outcome results
Primary
Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population
FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the mixed model repeated measures (MMRM) model and least square mean and standard error were calculated. The analysis was performed on ITT Population which comprised of all participants randomized to treatment and who received at least one dose of study medication.
Time frame: Baseline and Week 24
Population: ITT population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| FF/VI 100/25 mcg Once Daily | Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population | 0.019 Liter (L) | Standard Error 0.0107 |
| FP/S 250/50 mcg Twice Daily | Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population | 0.000 Liter (L) | Standard Error 0.0108 |
| FP 250 mcg Twice Daily | Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population | -0.104 Liter (L) | Standard Error 0.0109 |
95% CI: [-0.011, 0.049]
p-value: <0.00195% CI: [0.093, 0.153]Mixed Models Analysis
p-value: <0.00195% CI: [0.074, 0.134]Mixed Models Analysis
Primary
Change From Baseline in PM FEV1 Using Per Protocol (PP) Population
FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the MMRM models and least square mean and standard error were calculated. The analysis was performed on PP Population which comprised of all participants in the ITT Population who did not had any full protocol deviations.
Time frame: Baseline and Week 24
Population: PP Population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| FF/VI 100/25 mcg Once Daily | Change From Baseline in PM FEV1 Using Per Protocol (PP) Population | 0.020 L | Standard Error 0.012 |
| FP/S 250/50 mcg Twice Daily | Change From Baseline in PM FEV1 Using Per Protocol (PP) Population | 0.014 L | Standard Error 0.012 |
| FP 250 mcg Twice Daily | Change From Baseline in PM FEV1 Using Per Protocol (PP) Population | -0.099 L | Standard Error 0.0121 |
95% CI: [-0.027, 0.04]
p-value: <0.00195% CI: [0.086, 0.153]Mixed Models Analysis
p-value: <0.00195% CI: [0.08, 0.147]Mixed Models Analysis
Secondary
Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF)
PEF was measured using an electric flow meter each morning. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Time frame: Baseline and Weeks 1-24
Population: ITT Population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| FF/VI 100/25 mcg Once Daily | Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF) | 8.9 Liter per minute (L/min) | Standard Error 1.48 |
| FP/S 250/50 mcg Twice Daily | Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF) | 3.7 Liter per minute (L/min) | Standard Error 1.49 |
| FP 250 mcg Twice Daily | Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF) | -12.6 Liter per minute (L/min) | Standard Error 1.49 |
95% CI: [1.1, 9.4]
p-value: <0.00195% CI: [17.4, 25.6]ANCOVA
p-value: <0.00195% CI: [12.2, 20.4]ANCOVA
Secondary
Change From Baseline in PM PEF
PEF was measured using an electric flow meter each evening. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Time frame: Baseline and Weeks 1-24
Population: ITT Population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| FF/VI 100/25 mcg Once Daily | Change From Baseline in PM PEF | 5.5 L/min | Standard Error 1.55 |
| FP/S 250/50 mcg Twice Daily | Change From Baseline in PM PEF | 0.5 L/min | Standard Error 1.55 |
| FP 250 mcg Twice Daily | Change From Baseline in PM PEF | -13.7 L/min | Standard Error 1.55 |
95% CI: [0.7, 9.3]
p-value: <0.00195% CI: [14.9, 23.5]ANCOVA
p-value: <0.00195% CI: [9.9, 18.5]ANCOVA
Secondary
Change From Baseline in the Percentage of Rescue-free 24-hour Periods
The number of inhalations of rescue medication used during the day and night were recorded by participants using an electronic diary (e-diary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Time frame: Baseline and Weeks 1-24
Population: ITT Population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| FF/VI 100/25 mcg Once Daily | Change From Baseline in the Percentage of Rescue-free 24-hour Periods | -3.0 Percentage of rescue-free 24-hr periods | Standard Error 0.62 |
| FP/S 250/50 mcg Twice Daily | Change From Baseline in the Percentage of Rescue-free 24-hour Periods | -4.2 Percentage of rescue-free 24-hr periods | Standard Error 0.62 |
| FP 250 mcg Twice Daily | Change From Baseline in the Percentage of Rescue-free 24-hour Periods | -5.7 Percentage of rescue-free 24-hr periods | Standard Error 0.62 |
95% CI: [-0.5, 3]
p-value: 0.00295% CI: [0.9, 4.4]ANCOVA
p-value: 0.10695% CI: [-0.3, 3.2]ANCOVA
Secondary
Change From Baseline in the Percentage of Symptom-free 24-hour Periods
Change from Baseline in the percentage of symptom-free 24 hour period was evaluated. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value.Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Time frame: Baseline and Weeks 1-24
Population: ITT Population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| FF/VI 100/25 mcg Once Daily | Change From Baseline in the Percentage of Symptom-free 24-hour Periods | -3.5 Percentage of symptom-free 24 hour perio | Standard Error 0.67 |
| FP/S 250/50 mcg Twice Daily | Change From Baseline in the Percentage of Symptom-free 24-hour Periods | -4.7 Percentage of symptom-free 24 hour perio | Standard Error 0.67 |
| FP 250 mcg Twice Daily | Change From Baseline in the Percentage of Symptom-free 24-hour Periods | -6.2 Percentage of symptom-free 24 hour perio | Standard Error 0.67 |
95% CI: [-0.7, 3.1]
p-value: 0.00495% CI: [0.8, 4.5]ANCOVA
p-value: 0.11595% CI: [-0.4, 3.3]ANCOVA
Secondary
Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20
The ACT was a five-item questionnaire developed as a measure of participant's asthma control. The percentage of participants controlled, defined as having ACT score greater than or equal to 20 at the end of Week 24 were analyzed using logistic regression model with covariates of Baseline ACT score, region, sex, age and treatment group.
Time frame: Week 24
Population: ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FF/VI 100/25 mcg Once Daily | Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20 | 92 Percentage of participants |
| FP/S 250/50 mcg Twice Daily | Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20 | 93 Percentage of participants |
| FP 250 mcg Twice Daily | Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20 | 91 Percentage of participants |
95% CI: [0.53, 1.54]
p-value: 0.59595% CI: [0.69, 1.9]Regression, Logistic
p-value: 0.37295% CI: [0.75, 2.12]Regression, Logistic